Jens Brockmann
Overview
Explore the profile of Jens Brockmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
552
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schnitzbauer A, Filmann N, Adam R, Bachellier P, Bechstein W, Becker T, et al.
Ann Surg
. 2020 Sep;
272(5):855-862.
PMID: 32889867
Objective: The aim of this study was to evaluate the survival benefit of sirolimus in patients undergoing liver transplantation (LT) for hepatocellular carcinoma (HCC) (exploratory analysis of the SiLVER-trial). Summary...
2.
Katou S, Vogel T, Morgul H, Eichelmann A, Becker F, Slepecka P, et al.
Transplant Proc
. 2020 Aug;
52(9):2739-2741.
PMID: 32771247
A human immunodeficiency virus (HIV) infection is no longer an absolute contraindication for solid organ transplantation, yet such a setting is still challenging and little explored because of general reservations...
3.
Ali T, Broering D, Aleid H, Brockmann J, AlHumaidan H, Hammad E, et al.
Saudi J Kidney Dis Transpl
. 2019 Jun;
30(3):655-662.
PMID: 31249230
Although the outcomes of ABO-incompatible (ABOi) kidney transplant recipients are quite favorable, these patients are at increased risk of early antibody-mediated rejection (AMR) and graft loss. Some studies have also...
4.
Geissler E, Schnitzbauer A, Zulke C, Lamby P, Proneth A, Duvoux C, et al.
Transplantation
. 2015 Nov;
100(1):116-25.
PMID: 26555945
Background: We investigated whether sirolimus-based immunosuppression improves outcomes in liver transplantation (LTx) candidates with hepatocellular carcinoma (HCC). Methods: In a prospective-randomized open-label international trial, 525 LTx recipients with HCC initially...
5.
Vogel T, Utech M, Schmidt F, Holscher Keplin W, Diller R, Brockmann J, et al.
Nephrourol Mon
. 2015 Nov;
7(4):e27820.
PMID: 26539415
Background: Kidney transplantation has long been recognized as the best available therapy for end stage kidney disease. Objectives: This study aimed to compare outcomes of double-J versus percutaneous ureteral stent...
6.
Lehmann R, Graziano J, Brockmann J, Pfammatter T, Kron P, de Rougemont O, et al.
Diabetes Care
. 2015 Feb;
38(5):752-9.
PMID: 25665814
Objective: In patients with type 1 diabetes and end-stage renal disease, combined transplantation of a kidney together with a pancreas or isolated pancreatic islets are options to improve glycemic control....
7.
Bonani M, Rodriguez D, Fehr T, Mohebbi N, Brockmann J, Blum M, et al.
Kidney Blood Press Res
. 2014 Aug;
39(4):230-9.
PMID: 25118597
Background/aims: Sclerostin is secreted by osteocytes. As a circulating inhibitor of the Wnt-signaling pathway it inhibits bone formation and contributes to the development of osteoporosis. Sclerostin levels are elevated in...
8.
Guba M, Pratschke J, Hugo C, Kramer B, Pascher A, Pressmar K, et al.
Transpl Int
. 2012 Feb;
25(4):416-23.
PMID: 22320241
Early conversion to a calcineurin-inhibitor (CNI)-free maintenance immunosuppression with sirolimus (SRL), mycophenolate mofetil (MMF) and steroids was associated with an improved 1-year renal function as compared with a cyclosporine (CsA)-based...
9.
Chatzizacharias N, Vaidya A, Sinha S, Sharples E, Smith R, Jones G, et al.
Clin Transplant
. 2011 Oct;
26(3):387-92.
PMID: 21980989
The risk of progression to renal replacement after pancreas transplant alone (PTA) is a concern in patients with pre-transplant estimated glomerular filtration rate (eGFR) < 70 mL/min/1.73 m(2). This is...
10.
Chatzizacharias N, Muthusami A, Sullivan M, Sinha S, Brockmann J
Transplantation
. 2010 Dec;
90(10):1131-2.
PMID: 21157255
No abstract available.